ATLANTA, Feb. 20, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its fourth quarter and fiscal year 2013 financial results after the market close on Thursday, February 27, 2014. An investor conference call will follow on the same day at 4:30 p.m. ET. The conference call will be hosted by Dan Myers, President and Chief Executive Officer, and Rick Eiswirth, Chief Operating Officer and Chief Financial Officer. To participate in the call, please dial (877) 369-6586 (U.S. and Canada) or (253) 237-1165 (international). A live webcast will be available on the Investor Relations section of the corporate website at http://www.alimerasciences.com. A replay of the conference call will be available beginning February 27, 2014 at 7:30 p.m. ET and ending on March 6, 2014 by dialing (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international), Conference ID Number: 3470651. A replay of the webcast will be available on the corporate website for one week, through March 6, 2014. About Alimera Sciences, Inc. Alimera Sciences, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera's European operations are conducted from London by its wholly-owned subsidiary, Alimera Sciences Limited. Investor Contact:ICR, LLC John Mills310-954-1105 John.Mills@icrinc.com SOURCE Alimera Sciences, Inc.